Collectively, our data derived from cell lines, syngeneic mouse models, and specimen of patients with NSCLC revealed the prominent significance of TSC1/TSC2 mutations in promoting PD-L1 expression, facilitating T cell infiltration and augmenting tumor immunogenicity. This evidence concerns the gene TSC2 and non-small cell lung carcinoma.